FGFR1 and non-small cell lung carcinoma: Conversely, in the RAGNAR study, interim results showed that responses were reported in both FGFR1–4-altered squamous (n = 3/11, 27.3%) and non-squamous (n = 1/7, 14.3%) NSCLC who were treated with erdafitinib [27], suggesting that FGFR inhibitors may have a role to play in NSCLC.